American Association for Cancer Research



                                                                                                           APRIL 2009



Policy Forums will consider timely policy issues that affect cancer researchers

The AACR 100th Annual Meeting 2009, with the theme of "Science, Synergy and Success," will be held April 18-22 in Denver, Colorado. This year's meeting will feature three policy forums where attendees will have the opportunity to learn what the latest federal, state and local policies will mean for cancer research.

Also, attendees can visit the Main Internet Café in Lobby D or any of the mini-satellite stations throughout the convention center for easy online access to prepare and send a personal or specially prepared e-mail message or letter expressing concerns to your Members of Congress.

The locations and times listed below are subject to change - check the Online Proceedings and Itinerary Planner for the latest information.

Beyond the HIPAA Privacy Rule

When: Sunday, April 19, 2009, 2:30 p.m. - 4:00 p.m. (MST)

Where: Room 607, Colorado Convention Center


The study director and others will discuss and disseminate the findings in the newly released Institute of Medicine (IOM) study, "Beyond the Privacy Rule: Enhancing Privacy, Improving Health Through Research." It will begin with a brief overview of the HIPAA Privacy Rule and its requirements for researchers. The session will include a review of the currently available scientific evidence on the effect of the Privacy Rule on research. As part of the study process, the IOM commissioned a number of surveys of researchers' attitudes towards the Privacy Rule and also commissioned a survey of the public's attitude towards privacy in health research. The majority of the session will focus on the IOM committee's bifurcated recommendation to either develop a new approach to protecting privacy that would apply uniformly to all health research or revise the HIPAA Privacy Rule and associated guidance to better assure the protection of privacy in health research. Time will be allotted for questions.


Cancer Drug Development as a Successful Public-Private Enterprise - The NCI in Partnership with Industry

When: Monday, April 20, 2009, 1:30 p.m. - 3:00 p.m. (MST)

Where: Room 607, Colorado Convention Center


The development of new anticancer agents is a crucial process to winning the battle against cancer. Unfortunately, few efficacious agents emerge each year with the potential to make a difference in patients' lives. The principal stakeholders in the drug development process are industry, academic institutions and The National Cancer Institute. Developing successful collaborations among these three entities should accelerate drug discovery, optimization, production and evaluation in preclinical models and humans, making successful drugs available to patients earlier and in larger numbers. It is very important to avoid duplicative work and to concentrate the different steps on the individualized continuum for each drug to the groups with the expertise to deliver quick and valid results. This session will foster dialog between industry and government with input from the academic community. There will also be discussion about initiatives from the NCI to facilitate the success of compounds coming from industry and will engage the audience to discover needs and other potential initiatives that the NCI can make available to industry and academic investigators.

Session Leaders:

Miguel A. Villalona-Calero, M.D., Ohio State University Comprehensive Cancer Center, Columbus, Ohio

James A. Zwiebel, M.D., National Cancer Institute, Bethesda, M.D.


Impact of the New Administration's Priorities on Cancer Research

When: Tuesday, April 21, 2009, 11:30 a.m. - 1:00 p.m. (MST)

Where: Room 607, Colorado Convention Center

Description: How will the Obama Administration and the new Congress affect research? Significant changes to the health care system have been promised and pledges to support research could have a positive impact on the NIH and the NCI.  Dr. William S. Dalton, chairperson of the AACR Science Policy and Legislative Affairs Committee will lead a discussion of new federal initiatives that will have an impact on cancer research, how the new Congress and Administration will affect individual research work, and how scientists can help inform the political process so that wise policies are implemented.

Session Leader: William S. Dalton, M.D., Ph.D., H. Lee Moffitt Cancer Center and Research Center, Tampa, FL




Read More from the April Edition of the AACR Cancer Policy Monitor: